Japan's Drug Reimbursement Process and the Role of Chuikyo

1 Key Concepts from the Interview

The interview with a former **Central Social Insurance Medical Council (Chuikyo)** member provides rare insight into how Japan sets drug prices and decides reimbursement. For clarity, all references to specific products have been removed.

1.1 Chuikyo's composition and decision process

- **Tripartite council.** Chuikyo is an advisory body that helps the Ministry of Health, Labour and Welfare (MHLW) set the national fee schedule for medical services and drugs. The council consists of three groups: representatives of healthcare **providers** (medical associations, hospital federations), representatives from the **payer side** (health-insurance societies, employer groups and sometimes patient organisations) and **public interest members** (academics and other experts). This mix ensures that medical practice, payer finances and public welfare are all considered [1].

- **Focus on system-wide reimbursement, not individual contracting.** Chuikyo debates fee revisions every two years and decides whether newly approved drugs or devices should be included in the National Health Insurance (NHI) list. When the drug-pricing subcommittee reports that a product is safe and effective, Chuikyo decides whether the product should be reimbursed or left as self-pay. Because listing decisions apply uniformly to every insurer, there is no negotiation between manufacturers and individual insurers; a drug recommended by Chuikyo usually enters the NHI list within 6–7 weeks of approval.

- **Role of payer representatives.** The payer members of Chuikyo represent the financial sustainability of the national insurance system rather than the interests of a specific insurer. They monitor the predicted annual sales for a new product and flag those that could significantly strain the insurance budget. Payer representatives frequently question whether a premium is warranted but rarely change the final price. They are not free to accept or reject drugs individually; their role is to advocate for fiscal prudence within a consensus-driven council.

1.2 Drug-pricing expert organisation versus Chuikyo

- **Drug Pricing Expert Organisation (薬価専門組織).** Before Chuikyo deliberates, an expert committee evaluates new drugs for **safety and clinical effectiveness**. This sub-committee verifies whether trial evidence supports the drug and decides whether it meets the requirements for a "draft price" to be proposed. It does not set the official price; its role is to decide if the drug merits coverage and to propose a price based on predetermined formulas.

- **Chuikyo's decision.** Chuikyo does not re-evaluate clinical evidence; it receives the expert committee's report and debates whether to add the drug to the NHI list. In practice, once the expert group endorses a drug, Chuikyo almost always approves it because the clinical assessment

has already been made. However, Chuikyo will discuss whether reimbursement of a high-cost medicine could endanger the insurance budget and, if necessary, attach usage conditions (optimal use guidelines).

1.3 Pricing formulas and premiums

Japan's pricing system uses two primary methods [2]:

1. **Similar-efficacy comparison method (類似薬効比較方式).** If an existing drug of similar clinical value exists, the new drug's price is benchmarked to the reference product. A premium is added if the new drug offers superior efficacy or safety [3].
2. **Cost calculation (cost-plus) method (原価計算方式).** When no comparable product exists, the price is built up from manufacturing costs, R&D and profits [4]. Transparency of cost data is a persistent concern; in the interview the former Chuikyo member noted that for a high-cost personalised therapy, lack of disclosure led to an 80 % reduction in the proposed price. Cost inputs must be disclosed for premiums to be justified.

Premiums. MHLW may add premiums for innovation and orphan status. The interview noted that exceptional innovation can receive a **usefulness premium (有用性加算)** of up to ~45 % and a **marketability premium (市場性加算)** of 5–15 %. Premium categories are proposed by MHLW and debated by Chuikyo; payer representatives often argue for lower premiums but rarely overturn them.

1.4 MHLW's role in pricing and negotiation

- **Price proposal and negotiation.** The MHLW negotiates directly with manufacturers. If the drug's safety/effectiveness is confirmed, MHLW determines a draft price using either the similar-efficacy or cost-calculation formula and adds any applicable premiums. The ministry then submits the price proposal to Chuikyo. Chuikyo can approve, amend or reject the proposal, but it does not redo the price calculation. Thus the MHLW and manufacturers negotiate price parameters within the framework of national rules.

- **Uniform national price and listing.** MHLW publishes the official price in the NHI Drug Price List, which applies nationwide. Manufacturers cannot set their own prices and cannot offer rebates or confidential discounts to individual insurers. Coverage decisions are therefore centralized and apply to all citizens [5].

1.5 Cost-effectiveness evaluation and optimal-use guidelines

- **Post-listing cost-effectiveness analysis.** Since 2019 Japan has required formal cost-effectiveness evaluations for high-impact drugs after they are listed. Products with peak annual sales ≥ ¥10 billion or extremely high prices undergo a cost-effectiveness assessment by the Center for Outcomes Research and Economic Evaluation (C2H) [6]. The results can lead to price reductions (~5–15 %), but they do not affect initial reimbursement [7]. The interviewee gave the recent example of an Alzheimer's therapy whose price was cut by ~15 % after cost-effectiveness review.

- **Optimal Use Guidelines.** For very expensive or potentially over-utilised drugs, Chuikyo requires manufacturers to develop "optimal use" guidelines as a condition for reimbursement. These guidelines specify which patients are eligible, which physicians or hospitals may administer the drug, and when treatment should stop. They aim to ensure appropriate use and protect the insurance budget. Only high-cost drugs are subject to such guidelines.

2 Flowchart: From Approval to Reimbursement

The figure below summarizes the end-to-end process from regulatory approval to reimbursement under Japan's system. Each step is executed centrally and applies uniformly across the country.



3 Defining the "Payer" Role in Japan

In Japan there is **no analogue of US payers such as health-insurance companies or pharmacy benefit managers**. Instead, the functions of a payer are embedded in the national insurance system:

- **Embedded representation.** Payer interests are represented collectively in Chuikyo by members from health-insurance societies, employer groups and patient advocates. These representatives do not act on behalf of specific insurers but advocate for the financial sustainability of the universal insurance scheme.

- **No individual formulary or contracting.** Once Chuikyo approves a drug for inclusion, every insurer must reimburse it at the published price. Health-insurance societies cannot exclude a drug, negotiate rebates, impose prior authorization or create their own formularies. Their discretion is limited to administrative claims processing and monitoring overall expenditures.

- **Budget-impact perspective.** Payer representatives focus on whether a proposed price and expected sales volume could jeopardise the national insurance budget. They examine predicted patient numbers and revenues and may push for lower premiums or usage restrictions. However, they lack the authority to negotiate separate coverage terms. In this sense, the **payer** in Japan refers to the collective insurer membership of Chuikyo rather than independent decision makers.

4 Why Japan Has No US-style Payers

Several institutional features explain why US-style payers do not exist in Japan:

1. **National fee schedule and price uniformity.** All reimbursed services and drugs are paid according to a nationally determined fee schedule set by the MHLW based on Chuikyo's advice [5]. This eliminates the need for each insurer to set its own payment rates or negotiate with manufacturers.
2. **Centralized reimbursement decisions.** Listing a drug in the NHI Drug Price List is a national decision. Once a drug is listed, it must be reimbursed by all insurers; conversely, if it is not listed, it is not reimbursed. Insurers therefore have no authority to develop formularies or exclude products.
3. **Public insurance mandate.** Health insurance in Japan is compulsory and not-for-profit. Insurance societies are administrative entities that collect premiums and pay claims according to the national rules. They are prohibited from risk selection or coverage denial; thus they cannot leverage market power to negotiate price concessions.
4. **Built-in cost control mechanisms.** Japan uses uniform pricing, periodic price reductions and, for selected drugs, post-listing cost-effectiveness adjustments to control spending [6]. Because the government controls prices and volumes, there is less need for intermediary payers to manage utilization.

These factors mean that **price and reimbursement are decided centrally**, leaving insurers little discretion. As such, there is no market role for private payers comparable to those in the US.

5 Why Physicians (and KOLs) Are the Appropriate Research Targets

In the Japanese system, once a drug is listed it becomes universally reimbursable and its price and patient cost-sharing are fixed. Understanding market uptake therefore depends on **clinical adoption** rather than payer coverage. The interview and supplementary research highlight several reasons why physicians are the key stakeholders:

- **Prescribing drives utilisation.** Because all insurers reimburse listed drugs and there are no prior authorisation hurdles, whether a patient receives a new therapy depends almost entirely on the treating physician's judgment. Physicians decide whether a new drug offers sufficient clinical benefit and whether it is appropriate for their patients.

- **Guideline compliance and optimal use.** For high-cost drugs, Chuikyo mandates optimal use guidelines that specify patient eligibility and monitoring requirements. Physicians must understand and follow these guidelines; investigating their awareness and attitudes is essential for forecasting uptake.

- **Budget impact through clinical practice.** Although payer representatives monitor overall spending, real-world utilisation is determined by how widely physicians prescribe a drug. Overuse or off-label use could trigger budget concerns; therefore, understanding physician behaviour helps manufacturers anticipate policy responses.

- **Limited payer engagement.** Insurance officials rarely participate in external research; they generally reiterate official policy and have little operational discretion. As the interviewee noted, the payer side simply reviews predicted sales and urges fiscal caution. Consequently, payer interviews yield little actionable insight into market dynamics.

Conclusion: For market research in Japan, interviewing physicians and key opinion leaders (KOLs) is far more informative than speaking with payer representatives. Physicians decide how and when to use new therapies within the bounds of national guidelines, making their perspectives critical for understanding market potential.

6 Summary for Overseas Pharma Market Researchers

Japan's reimbursement system is characterised by **centralised pricing, uniform coverage and a strong emphasis on clinical value and fiscal sustainability**. Chuikyo, a tripartite council with payer, provider and public representatives, advises the MHLW on whether to reimburse a new drug and at what price. Clinical safety and efficacy are assessed by a dedicated expert committee; pricing follows either a similar-efficacy comparison or cost-plus method, with premiums for innovation and orphan status. MHLW negotiates with manufacturers and proposes the price; once Chuikyo approves, the price becomes the national standard and applies to all insurers. High-cost drugs may be subject to post-listing cost-effectiveness evaluations and optimal-use guidelines.

This centralised structure means there are **no independent payers** like those found in the US. Instead, payer interests are consolidated in Chuikyo, and insurers must follow national decisions. Consequently, **physicians are the true gatekeepers of utilisation**—they decide whether and how to prescribe newly reimbursed drugs, subject to guidelines. Market research that aims to understand the Japanese environment should focus on physicians' perceptions of clinical value, unmet needs and guideline interpretation rather than on payer negotiations. The flowchart above summarises the key steps from PMDA approval to nationwide reimbursement and highlights the roles of each stakeholder.

---

1 2 3 4 5 Price setting of medicines and medical devices | C2H｜Center for Outcomes Research and Economic Evaluation for Health
https://c2h.niph.go.jp/en/assessment/price-setting/

6 7 POV_3Q22_The-Evolution-of-HTA-Drug-Prices-Japan-_EVERSANA.pdf
https://www.eversana.com/wp-content/uploads/2022/09/POV_3Q22_The-Evolution-of-HTA-Drug-Prices-Japan-_EVERSANA.pdf